thyroid cancer
Veracyte Q2 Revenues up 27 Percent on Prostate, Thyroid Tests; Firm Raises Full-Year Guidance
The company said that it set records for test volume for both its Decipher Prostate test and Afirma assay for thyroid nodule risk stratification.
Veracyte Core Tests Maintain Growth as Firm Prepares to Shift Resources to Newest Acquisitions
Premium
The company is anticipating that its new MRD platform, acquired earlier this year, will be fuel for significant future development and expansion.
Polygenic Risk Scores Help Inform Adult Cancer Risk in Childhood Cancer Survivors
Researchers found that cancer-specific PRS and individuals' history of high radiation treatment could help predict development of a handful of adult cancer types.
Veracyte Q4 Revenues Grow 22 Percent, Topping Estimates
Veracyte reported Q4 revenues of $98.2 million driven by strong sales of its Afirma thyroid cancer and Decipher prostate cancer tests.
Local Coverage Determinations Roundup: Veracyte, Sonic Healthcare USA, Tempus
A roundup of local coverage determinations from Medicare administrative contractors.
Jan 31, 2020
Dec 20, 2019